PTEN is frequently inactivated in various malignancies, such as brain, prostate, endometrial, gastric cancers and NSCLC, and clinical data have suggested that PTEN loss of function occurs in 10%–25% of NSCLC cases (Liu et al., 2022). This evidence concerns the gene PTEN and gastric cancer.